Chemotherapy of vesical and prostatic tumours.
D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001761:Bleomycin / Q000627:therapeutic use; D003036:Cobalt Isotopes; D003556:Cystitis / Q000139:chemically induced; D003630:Daunorubicin / Q000627:therapeutic use; D005009:Ethoglucid / Q000627:therapeutic use; D005472:Fluorouracil / Q000627:therapeutic use; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use; D008937:Mitomycins / Q000627:therapeutic use; D009588:Nitrogen Mustard Compounds / Q000009:adverse effects; D010212:Papilloma / Q000188:drug therapy; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy; D013852:Thiotepa / Q000009:adverse effects; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy
D000903:Antibiotics, Antineoplastic; D000970:Antineoplastic Agents; D003036:Cobalt Isotopes; D008937:Mitomycins; D009588:Nitrogen Mustard Compounds; D001761:Bleomycin; D005009:Ethoglucid; D013852:Thiotepa; D005472:Fluorouracil; D006918:Hydroxyurea; D008727:Methotrexate; D003630:Daunorubicin